Published in Cancer Weekly, June 2nd, 1997
Data were presented from a clinical trial of 39 patients with an investigational compound known as CMA-676. The compound is being co-developed by Celltech plc (UK) and Wyeth-Ayerst Research of Radnor, PA. The study was intended to determine the appropriate dosing for leukemia patients. During this process, the product displayed preliminary evidence of efficacy, with two patients achieving complete remission...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.